DTIL, US74019P2074

Precision BioSciences stock fell 1.74 percent on October 6

Published on 10/08/2026 at 04:09 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Precision BioSciences stock carried a USD 172.5 million market value on October 7, 2026. Q2 cash of USD 112 million supported a runway through 2028.

DTIL, US74019P2074, Illustration mit AI erstellt.

Precision BioSciences (ISIN US74019P2074) closed at USD 6.20 on Nasdaq on October 6, 2026, down 1.74 percent. The price report leaves the gene-editing company 35.6 percent below its 52-week high of USD 9.62 and 75.6 percent above its low of USD 3.53.

Stock stays below yearly high

The October 6 session ranged from USD 6.11 to USD 6.40, while Precision BioSciences had a market capitalization of USD 172.5 million as of October 7, 2026. The comparison shows that the stock remains closer to its yearly low than its yearly high, despite the 52-week spread.

Precision BioSciences trades under the ticker DTIL and uses its ARCUS genome-editing platform to develop in vivo therapies. The company is focused on clinical programs for chronic hepatitis B and Duchenne muscular dystrophy.

Cash supports clinical milestones

At the September 16, 2026 H.C. Wainwright presentation, Investing.com reported that Precision held USD 112 million in cash and cash equivalents at the end of Q2 2026 and expected funding to extend through 2028. The same presentation said PBGENE-DMD had begun dosing patients and that initial safety data were expected by the end of 2026.

The financial runway matters because both lead programs remain in early clinical testing. Investing.com also described the need for additional data before investors can assess how ARCUS performs in patients.

Consensus target exceeds USD 29

A consensus compiled by Simply Wall St on October 7, 2026 rated the stock Strong Buy among five analysts. The average 12-month price target was USD 29.40, with a low of USD 18.00 and a high of USD 60.00, putting the average target 374.19 percent above the October 6 close of USD 6.20.

The next earnings report is listed for November 10, 2026, according to Investing.com. That date gives investors a defined checkpoint for cash usage, clinical progress and the companys path toward its planned year-end safety update.

Nasdaq price remains the key measure

Precision BioSciences stock closed at USD 6.20 on Nasdaq on October 6, 2026. The next valuation test is whether clinical milestones can narrow the gap between the USD 6.20 share price and the USD 29.40 consensus target without changing the early-stage risk profile.